{"id":"NCT02614287","sponsor":"Eli Lilly and Company","briefTitle":"A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura","officialTitle":"A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-11-30","primaryCompletion":"2017-05-12","completion":"2018-08-14","firstPosted":"2015-11-25","resultsPosted":"2019-01-07","lastUpdate":"2020-06-17"},"enrollment":270,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Migraine"],"interventions":[{"type":"DRUG","name":"Galcanezumab","otherNames":["LY2951742"]}],"arms":[{"label":"Galcanezumab 120 mg","type":"EXPERIMENTAL"},{"label":"Galcanezumab 240 mg","type":"EXPERIMENTAL"}],"summary":"The main purpose of this study is to evaluate the longer term safety of the study drug known as galcanezumab in participants with episodic or chronic migraine.","primaryOutcome":{"measure":"Percentage of Participants Who Discontinued Due to Adverse Event","timeFrame":"Baseline through Month 12","effectByArm":[{"arm":"Galcanezumab 120 mg","deltaMin":4.65,"sd":null},{"arm":"Galcanezumab 240 mg","deltaMin":4.96,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"1"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":27,"countries":["United States","Belgium","Canada","France","Hungary","Puerto Rico"]},"refs":{"pmids":["32576229","31952501","31482569","30413151"],"seeAlso":["http://www.lillytrialguide.com/EN-US/studies/headache/cgaj"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":129},"commonTop":["Injection site pain","Viral upper respiratory tract infection","Back pain","Upper respiratory tract infection","Injection site reaction"]}}